Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > ADXS.OB > Summary

More on ADXS.OB

Advaxis Inc.
(ADXS.OB)

0.163USD   Up0.007 (4.49%)   
At 2:29AM IST
 Advaxis Inc. (OTC BB:ADXS.OB) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y 
Last Trade: 0.163USD
Trade Time:2:29AM IST
Change:Up0.007 (4.49%)
Prev Close:0.156
Open:0.16
Bid:0.161 x 5000
Ask:0.164 x 5000
1y Target Est:N/A
Day's Range:0.155 - 0.18
52wk Range:0.02 - 0.21
Volume:2,911,545
Avg Vol (3m):890,316
Market Cap:18.85M
P/E (ttm):N/A
EPS (ttm):-0.014
Div & Yield:N/A (N/A%)
Add ADXS.OB to Portfolio   Download Data

HEADLINES

 
•Cancer Research UK to Fund Clinical Trial of ADXS11-001 for the Treatment of Head and Neck Cancer - Business Wire  - Wed 1:30AM
•Advaxis to Present at the BIO CEO & Investor Conference - Business Wire  - Tue 1:23AM
•ADVAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - EDGAR Online  - Sat, Feb 6
•Advaxis Chairman/CEO Thomas A. Moore Interviewed - Business Wire  - Tue, Feb 2
•Advaxis Receives $278,978 in Non-Dilutive Tax Credit Sale - Business Wire  - Wed, Jan 27
•Advaxis Issued New Intellectual Property Patent - Business Wire  - Fri, Jan 22
•ADVAXIS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers - EDGAR Online  - Tue, Jan 12
•Advaxis to Present at the Sidoti Microcap 2010 Investor Conference - Business Wire  - Fri, Jan 8
•Advaxis Awarded European Patent for New Listeria Vector - Business Wire  - Mon, Jan 4
•Fifteen Percent of ADXS11-001 Treated Cervix Cancer Patients Still Alive Three Years after Initial Dosing - Business Wire  - Tue, Dec 29
» More Headlines for ADXS.OB...

BUSINESS SUMMARY

 
Advaxis, Inc., a development stage biotechnology company, engages in the research and development of new cancer-fighting techniques primarily in the United States.

» Full Company Profile